Long Ideas - PropThink’s readers will be aware of our bullish outlook on Sarepta Therapeutics (SRPT), and Thursday’s commentary that a NDA filing may still be months away … Continue Reading
Read NowLong Ideas - Shares of Keryx Biopharmaceuticals (KERX) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to … Continue Reading
Read NowLong Ideas - Sunshine Heart has rallied 20% since dropping to $5.00 in mid-May following an equity financing. PropThink’s subscribers knew to buy the dip, and on Monday, … Continue Reading
Read NowLong Ideas - Stemline Therapeutics (STML) completed its IPO in January of this year, (the company was founded in 2003), and as its name implies, the company develops cancer therapies … Continue Reading
Read NowLong Ideas - It doesn’t get much better than this, and Synergy Pharmaceuticals (SGYP) remains a favorite PropThink idea. The company’s lead drug candidate, plecanatide, has demonstrated strong … Continue Reading
Read NowLong Ideas - Things are looking up for Cubist Pharmaceuticals (CBST). As we speculated last week, a key piece of Cubist’s ongoing litigation with Hospira has gone in … Continue Reading
Read NowLong Ideas - Cell therapy developers Athersys and Cytomedix target the immense stroke treatment market. Mr. Napodano laid out the theses for these two stem cell developers, although … Continue Reading
Read Now